A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Markus ZeitlingerMartin BauerRoman Reindl-SchwaighoferRobert M StoekenbroekGilles LambertEvelyn Berger-SieczkowskiHeimo LaglerZoe OesterreicherBeatrix WulkersdorferPetra LührsGergana GalabovaCarsten SchwenkeRobert M MaderRossella MedoriChristine LandlingerAlexandra KutzelniggGünther StafflerPublished in: European journal of clinical pharmacology (2021)
EudraCT: 2015-001719-11. ClinicalTrials.gov Identifier: NCT02508896.